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Abstract
Background
Across European countries, differences exist in biosimilar policies, leading to variations in
uptake of biosimilars and divergences in savings all over Europe.
Objectives
The aim of this article is to provide an overview of different initiatives and policies that may
influence the uptake of biosimilars in different European countries. Recommendations will
be formulated on how to create sustainable uptake.
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Methods
An overview of policies on biosimilars was obtained via a questionnaire, supplemented with
relevant articles. Topics were organized in five themes: availability, pricing, reimbursement,
demand-side policies, and recommendations to enhance uptake.
Results
In all countries studied, biological medicines are available. Restrictions are mainly depen-
dent on local organization of the healthcare system. Countries are willing to include biosimi-
lars for reimbursement, but for commercial reasons they are not always marketed. In two
thirds of countries, originator and biosimilar products may be subjected to internal reference
pricing systems. Few countries have implemented specific incentives targeting physicians.
Several countries are implementing pharmacist substitution; however, the scope and rules
governing such substitution tend to vary between these countries. Reported educational pol-
icies tend to target primarily physicians, whereas fewer initiatives were reported for patients.
Recommendations as proposed by the different country experts ranged from the need for
information and communication on biosimilars to competitive pricing, more support for
switching and guidance on substitution.
Conclusions
Most countries have put in place specific supply-side policies for promoting access to biosi-
milars. To supplement these measures, we propose that investments should be made to
clearly communicate on biosimilars and educate stakeholders. Especially physicians need
to be informed on the entry and use of biosimilars in order to create trust. When physicians
are well-informed on the treatment options, further incentives should be offered to prescribe
biosimilars. Gainsharing can be used as an incentive to prescribe, dispense or use biosimi-
lars. This approach, in combination with binding quota, may support a sustainable biosimilar
market.
Introduction
Biological medicinal products are widely used, e.g., in treatment of autoimmune diseases and
cancer, targeting key disease mediators [1]. They are often expensive and continued growth in
market share and expenditure is expected in the coming years [2]. This trend puts pressure on
already restricted healthcare budgets and may lead to a decrease in patient access to treatment
[3]. However, as patents and other exclusivity rights on many high-selling and expensive bio-
logical medicinal products are expiring or have expired, non-innovator versions of these bio-
logicals, i.e. biosimilars, may enter the market. Biosimilars are lower cost, but equally effective
and safe, alternatives of originator biologicals and may bring relief to pressurized healthcare
budgets. In 2016, IMS Health estimated that biosimilars could lead to savings up to €100 bil-
lion by 2020 in the United States (US) and the five major countries in the European Union
(EU) [4]. In Europe, a legal framework for marketing authorization of biosimilars was estab-
lished in 2004 [5], and as for all biotechnological products, biosimilars receive marketing
authorization via the centralised procedure [6]. The EMA defines a biosimilar as “a biological
medicinal product that contains a version of the active substance of an already authorized origi-
nal biological medicinal product (reference medicinal product) in the European Economic Area
Policies for biosimilar uptake in Europe
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(EEA). Similarity to the reference medicinal product in terms of quality characteristics, biological
activity, safety and efficacy based on a comprehensive comparability exercise needs to be estab-
lished”.[7] In 2006 the European Medicines Agency (EMA) approved the first biosimilar, Omni-
trope1 (somatropin). Since 2006, several product-specific biosimilar guidelines were developed
by the EMA [8], and 28 biosimilars have been approved for use in the EU as of June 2017 [9].
After granting marketing authorization to a medicinal product at the European level, local
implementation is up to the Member States, and consequently each country can formulate its
own biosimilar policies. Differences exist in the pricing and reimbursement procedures, levels
of education, characteristics of covered population, and incentivization of stakeholders, lead-
ing to variations in uptake of biosimilars [10] and divergences in savings from biosimilars use
across Europe, and eventually even within the same country [11]. Experiences from different
European countries with biosimilar policies may offer useful insights into current and future
uptake of biosimilars.
The aim of this article is to provide an overview of the different initiatives and policies that
may influence the uptake of biosimilars, undertaken by health authorities in different Euro-
pean countries. These policies may concern pricing, reimbursement, educational initiatives
and incentives for physicians, pharmacists and patients. In 2014, European Biopharmaceutical
Enterprises (EBE) conducted a survey to examine pricing and reimbursement policies of off-
patent biological medicines in European countries [12]. Our study aims to provide an update
on the developments in the biosimilar market and to add value to this survey on various
aspects. Incentives for physicians, pharmacists and patients are studied, broadening the scope
of the analysis. Furthermore, an additional type of correspondents is included, i.e. the national
health authorities, who have introduced these pricing, reimbursement or uptake measures.
Our study also includes the new generation of biosimilar monoclonal antibodies, which
entered the market in 2015 and are now in full expansion. Three recent articles investigated
policies for biosimilars in Europe [13–15], each relying on a literature review to determine
existing policies. In contrast, our study used close collaboration with national experts to gain
insight in the biosimilar market of their country. These recent articles [13–15] emphasized the
need for a better understanding of what drives biosimilar uptake and the establishment of a
robust policy framework. Therefore, our study aims to further clarify, with a different method-
ology, which policies exist. Furthermore, based on the survey results, recommendations will be
formulated on how to create a sustainable uptake of biosimilars in Europe.
Methods
An overview of policies on biosimilars used in European countries was obtained via a ques-
tionnaire, administered to different country experts, and supplemented with relevant articles.
Topics for the questionnaire were derived from previous work on generic medicines [16] and
The Belgian Health Care Knowledge Centre (KCE) report 199 on biosimilars [17]. Topics
were organized in five themes: the availability of biosimilars, pricing policies, reimbursement
policies, demand-side policies (broken down by the 4Es–Education, Engineering, Economics
and Enforcement [18]), and recommendations to enhance uptake of biosimilars. Open as well
as closed questions were included. The questionnaire was written in English. The question-
naire as updated in August 2016 can be consulted as supporting information (S1 Question-
naire). All molecules for which a biosimilar was marketed in Europe at that time (filgrastim,
somatropin, erythropoietin alfa, insulin glargine, follitropin, infliximab and etanercept) were
included. This article presents several highlights from this extensive questionnaire. Results
were rearranged in three themes: i) availability of biosimilars, ii) national policies, and iii) rec-
ommendations from the country experts.
Policies for biosimilar uptake in Europe
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A pilot survey was carried out in two countries (Slovenia, Lithuania) to validate the ques-
tions in terms of clarity, after which the refined questionnaire was sent out to experts of differ-
ent European countries with knowledge of the biosimilar market. These experts were initially
contacts within the Piperska Group [19], which is a network of professionals doing research
on the rational use of medicines. These contacts were then further supplemented with other
contacts in the network of the KU Leuven / Erasmus MC team. Country experts represented
regulatory authorities in different European countries, pricing and reimbursement authorities,
health insurance companies, health technology assessment (HTA) bodies, procurement agen-
cies, and academia, and were contacted via e-mail or telephone to participate in this study.
Initially, one expert per country was contacted. This expert acted as the national contact,
responsible for collecting data for the survey, and contacting additional national stakeholders.
When responses were not clear, clarification was requested via e-mail or phone calls. This
approach was used before when assessing different policies and their impact, as well as debat-
ing key issues such as managed entry agreements, personalized medicine and new models to
enhance the managed entry of new medicines [20–26]. The data obtained via the questionnaire
were supplemented with relevant articles, and, if possible, responses were validated by contact-
ing other experts in the individual countries. Descriptive statistics were used to analyze the
data, with frequencies being reported where appropriate, and open questions being examined
via qualitative analysis. During critical review of the manuscript, the experts were asked to
include data collected until the end of April 2017. Data was collected between November 2015
and May 2017.
Results
Data were obtained from 24 countries, 20 EU Member States, plus Iceland, Norway, Russia,
and Serbia. The 20 EU Member States, and European Economic Area (EEA) countries Iceland
and Norway, fall within the scope of the centralized marketing authorization in line with Regu-
lation (EC) No 726/2004 [6]. This contrasts with Russia and Serbia where authorization of bio-
similars is the responsibility of the national health authorities. At the time the study was
carried out, biosimilars for filgrastim, somatropin, erythropoietin alfa, insulin glargine, folli-
tropin, infliximab and etanercept had been launched in the European market. In the following
paragraphs, results for the different themes in the questionnaire are presented: i) availability of
biosimilars throughout Europe, ii) national policies for biosimilars, subdivided in pricing,
reimbursement and demand-side policies, and iii) recommendations to enhance uptake of
biosimilars as proposed by the different country experts.
i) Availability of biosimilars
Although biosimilars are approved via the EMA and thereby receive marketing authorization
in the European Union, availability of biosimilars can differ across countries. Availability in
our study is defined as marketed by the marketing authorization holder in a specific country,
but not necessarily funded. As can be seen in S1 Table, biologicals, including biosimilars, of
the aforementioned active substances are mainly available in the hospital setting, although
most countries also make them available in ambulatory care. In all countries studied, biological
medicines are available. Restrictions are mainly dependent on local organization of the health-
care system. Insulin is a product that is typically dispensed via ambulatory care and addition-
ally via hospitals, while infliximab is mainly a hospital product.
Since biologicals are often expensive, funding is necessary to support patient access to these
treatments. S2 Table shows which biosimilars are funded in the selected countries, as of April
2017. Whether a specific product is available in a given country, in most cases is a commercial
Policies for biosimilar uptake in Europe
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decision of the marketing authorization holder and not of a regulatory or reimbursement
agency.
For filgrastim, seven biosimilars are currently authorized, which are marketed by five differ-
ent companies [9]. As can be seen in S2 Table, the biosimilars of filgrastim that are funded in
most countries are, in decreasing order, Zarzio1, Nivestim1, Tevagrastim1, and Accofil1.
When an epoetin alfa biosimilar is funded in a country, Binocrit1 or Retacrit1 is chosen. In
some countries, no biosimilar for epoetin is funded. This is the case in Estonia, Iceland, Malta,
and Russia. In all countries, except Malta, biosimilar somatropin, Omnitrope1, is funded
(which is the only biosimilar of somatropin that is authorized). In 18 out of 24 countries, Aba-
saglar1, biosimilar insulin glargine, is funded. On the biosimilar follitropin market, Bemfola1
or Ovaleap1 is funded in all countries, except for Austria, Malta, Russia, and Serbia. With
respect to infliximab biosimilars, in almost all countries, Inflectra1 as well as Remsima1 are
funded. Five countries have Flixabi1 on the market, which received approval from the EMA
in May 2016. Benepali1 (biosimilar etanercept) was approved by the EMA in January 2016
and is funded in 14 of the 24 countries.
Germany was the only country in which all registered biosimilars are available and funded.
It should be noted that Russia has a different regulatory system from that of the EU, and has
many more non-innovator versions of biologicals than indicated in S2 Table. For comparison,
S2 Table, only includes EMA approved biosimilars. Also other countries reported the use of
non-originator products and next-generation biologicals. For example, in Iceland Neorecor-
mon1 (epoetin beta) is commonly used, but no biosimilars of epoetin are funded. In Malta no
biosimilars of epoetin are funded (they are not supplied), but Eporatio1 (epoetin theta) is.
ii) National policies
Pricing. In all countries, prices of medicinal products used in ambulatory care are regu-
lated by national authorities, although differences in scope and extent of involvement exist.
Table 1 provides an overview of biosimilar pricing mechanisms for the different countries.
The most frequent biosimilar pricing mechanisms in ambulatory care are pricing a percentage
below the price of the originator medicinal product, and the use of a maximum price. The per-
centage can be fixed or a range subject to negotiation. Maximum prices are often set by exter-
nal reference pricing, as is the case in Bulgaria, Czech Republic, Iceland, Malta, Latvia, Serbia,
and Slovenia. Other mechanisms can also be used to determine the price of the biosimilar for
ambulatory care, including free pricing (e.g., Germany, UK), free pricing without exceeding
the price of the reference product (e.g., Norway), market forces (e.g., Russia), national tender-
ing (e.g., Malta, Serbia), HTA (e.g., Sweden), and officially same price as reference product
(e.g., the Netherlands). In most countries, no single pricing mechanism is used to determine
the price of the biosimilar in ambulatory care, but multiple pricing mechanisms are combined.
For medicinal products used in the hospital setting, tenders occur in all countries, either at
a national level or by individual hospitals, and biosimilars may be included. In Belgium, there
is a national list price for hospital medicinal products, but the price at hospital level may vary,
since hospitals tender individually or in groups. In Malta and Serbia, just as for medicinal
products used in ambulatory care, also hospital medicinal products are procured by national
tendering. National tendering, organized by the Norwegian Hospital Procurement Trust, Divi-
sion Pharmaceuticals (legemiddelinnkjøpssamarbeid, LIS), also occurs among the hospital
group in Norway, where large discounts can be observed (a 69% discount of biosimilar inflixi-
mab on the originator medicinal product in 2015, and a 60% discount in 2016) [27]. There is a
clear trend towards using international nonproprietary names (INN) in the preparation of ten-
ders. However, tendering by brand name, or other mechanisms (e.g., grouping by indication
Policies for biosimilar uptake in Europe
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Table 1. Policies for biosimilars in different countries in Europe (April 2017).
Country Biosimilar pricing in ambulatory care Internal reference
pricing
Incentives to
prescribe
Substitution
Austria First biosimilar: -38% on reference product.
Second biosimilar: -15% on first biosimilar.
Third biosimilar: -10% on second biosimilar.
The reference product has to lower its price by 30% three months after the first
biosimilar’s entry into reimbursement. After the third biosimilar has entered into
reimbursement, the reference product has to match the price of the cheapest
available biosimilar in the Code of Reimbursement.
All subsequent entries need to offer a rebate of €0.10 on the cheapest alternative.
The requested percentage discount for entry into reimbursement of the first
biosimilar of a given reference product was decreased in March 2017 making it
easier for biosimilars to be included in the Code of Reimbursement, while the
mandatory discounts for generic follower medicines were slightly increased.
Before that legal reform, both groups of follower medicines had been treated
equally.
Yes Yes No
Belgium The price of the biosimilar is negotiated on a case per case base, where the
maximum price in order to be reimbursed may not exceed the price of the
reference product (class 2 reimbursement).
Obligatory price reduction for the reference product when the biosimilar enters the
market.
No Yes No
Bulgaria The manufacturers’ price of the biosimilar cannot be higher than the lowest price
of the same medicine in the reference countries for Bulgaria: Romania, France,
Latvia, Greece, Slovak republic, Lithuania, Portugal, Italy, Slovenia, Spain,
Belgium, Czech republic, Poland, Hungary, Denmark, Finland, Estonia. Then a
regressive margins scale at 3 levels exists and ceiling retail price is calculated and
published officially.
Yes No No
Croatia The price of the biosimilar is determined via external reference pricing (Italy,
Slovenia, Czech Republic, Spain, and France).
First biosimilar: -15% on reference product.
Next biosimilars: -10% on previous biosimilar.
Yes No No
Czech
Republic
Amendment to Act No. 48/1997 Coll., on Public Health Insurance (1st April 2017):
The price and reimbursement of the first biosimilar is cut down by 30% (previously
15%) of the price of the reference product. The statutory price of the reference
product remains the same, but the reimbursement level is lowered to the price of
the biosimilar.
The maximum price of the biosimilar is determined via external reference pricing:
All EU countries except for Bulgaria, Czech Republic, Estonia, Luxembourg,
Germany, Austria, Romania, Cyprus, and Malta.
Yes No No
England (UK) Regulated market, but free pricing by the company.
Pharmaceutical price regulation scheme (PPRS): a government negotiated
process for branded medicines (4–5 years) with The Association of the British
Pharmaceutical Industry (ABPI). The latest PPRS negotiations have volume
based pricing scheme. If total amount (£) of medicines sold is above the threshold
then the government gets a rebate. Biosimilars go predominantly via hospitals,
therefore primary care price or the NHS National tariff is less relevant.
No Yes No
Estonia The price of the biosimilar is negotiated. For ambulatory use the price has to be at
least 15% below the price of the reference product. For hospital use, there is no
fixed percentage.
Yes Yes Yes
Finland The price of the biosimilar must be below the price of the reference product. The
wholesale price of the first reimbursable biosimilar must be at least 30% lower
than the approved wholesale price of the reference product. Once the biosimilar is
launched, the price of the originator will be re-examined.
No Yes No
France Prices are fixed upon negotiation between pharmaceutical companies and the
Economic Committee for Medicinal Products (CEPS), typically 10–20% below the
price of the reference product, taking into account a range of factors including the
drug’s improvement in medical benefit (ASMR) rating versus therapeutic
equivalents (Biosimilars are given an ASMR rating of V), the price of the drug in
the rest of Europe, and sales volume forecasts.
Yes Yes Yes
(Continued )
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Table 1. (Continued)
Country Biosimilar pricing in ambulatory care Internal reference
pricing
Incentives to
prescribe
Substitution
Germany The price of the biosimilar is freely set by the company. Discounts may be
negotiated through tenders by individual healthcare funds.
Yes Yes Yes/No
Iceland The price of the biosimilar must not be higher than the lowest wholesale price of
four countries: Denmark, Norway, Sweden, and Finland.
When the biosimilar is on the market, the price of the reference product shall be
reduced to 80% of the original ex-factory price.
No Yes No
Ireland The price of the biosimilar is negotiated, typically 10–20% below the price of the
reference product.
No No No
Italy In general, biosimilars are priced approximately 20% below the price of the
reference product, with external reference pricing being used as supporting
information for pricing reimbursed medicines.
No Yes, in some
regions
No
Latvia Biosimilar drugs are evaluated by general principles applied to generics:
First biosimilar: at least -30% on reference product.
Second and third biosimilar: at least -10% on first/second biosimilar
Next biosimilars: -5% further decrease
The price may not be higher than the third lowest price in Czech Republic,
Romania, Slovakia, Hungary, and Denmark, and not higher than the price in
Estonia and Lithuania.
Yes No Yes
Malta A maximum price is set for national procurement and this maximum is set through
reference pricing (based on a basket of countries). The Centralised Supplies Unit
procures medicines by tendering. The specifications for procurement are by INN
and do not specify a brand name, allowing biosimilars and originator products to
compete in the same procurement procedure.
No No No
Netherlands The price of the biosimilar is officially the same as the price of the reference
product.
Yes No No
Norway The price of the biosimilar cannot be higher than the price of the reference
product. The vendor decides the price below this level.
No Yes No
Poland First biosimilar: -25% on reference product.
Second biosimilar: Must be cheaper than the first.
Limit groups exist where the cheapest is the limit for the whole group.
Data from EU and EFTA have to be presented.
Yes No Yes
Portugal External reference pricing, with change in reference countries each year (2017:
Spain, France and Italy), to establish the first maximum price.
To be reimbursed, the price of the biosimilar must be at least 20% lower than the
price of the reference product.
No Yes, in hospitals No
Russia 90% of the price of the ‘reference product’ (first in Russia) for reimbursement.
Market forces determine the price of the biosimilar when not reimbursed.
Yes No Yes
Serbia First biosimilar: -30% on reference product, setting the reimbursement rate.
Second biosimilar: -10% on first biosimilar.
Third biosimilar: -10% on second biosimilar.
With a maximum of 90% of the average price of the corresponding biosimilar in
Slovenia, Croatia, and Italy.
National tendering by brand name can occur.
Yes No No
Slovenia If the same biosimilar medicinal product is on the market in one of the reference
countries for Slovenia or in any other EU/EEA country, the price is respectively
92% of the lowest price of the biosimilar in the reference countries (Austria,
Germany and France) or 92% of a median price in other EU/EEAC countries. If the
biosimilar is not on the market in any of the reference countries or EU/EEAC
countries, 68% of the price of the reference product is the price of the biosimilar.
JAZMP determines maximum allowed price of all medicinal products (in
exceptional cases also exceptional higher allowed price), including biosimilars.
At the level of pricing, no negotiations take place. Prices are negotiated by the
reimbursement body, individual hospitals and in public procurement.
Yes No No
Spain The price of the biosimilar is negotiated, typically 25–30% below the price of the
reference product. A maximum price is set as a reference price for national
procurement.
Yes Yes, in some
regions
No
(Continued )
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or therapeutic class) are used as well. The latter is commonly used in Poland, England and
France.
Reimbursement. In all countries reimbursement is a matter of national authorities. In
Italy, England and Russia, also regional budgets can be involved. In England, the decision to
reimburse a medicinal product is made by different commissioners depending upon their
therapeutic class, e.g., biosimilars of cancer drugs will be reimbursed by National Health Ser-
vice England and biosimilars of TNF-alpha inhibitors by clinical commissioning groups. In
Russia, it is possible for individual regions to create their own programs which supplement the
national one.
In the majority of countries, reimbursement is granted for all indications authorized, and
not only the indications for which a clinical trial was conducted, as is the case in Croatia and
Serbia. In Malta, a protocol exists which specifies the conditions for reimbursement, for exam-
ple, when a product is not approved as a first-line treatment, it specifies the previous treatment
failure before another product can be reimbursed. In Bulgaria, reimbursement in ambulatory
care for some biosimilars is based on their International Classification of Diseases (ICD) code
[28], while reimbursement for use in the hospital setting is usually granted according to the
marketing authorization. This is the case with epoetin, which in ambulatory care is reimbursed
only for chronic kidney disease, while in hospitals reimbursement is granted for all authorized
indications.
In two thirds of the countries, the originator medicinal product and biosimilar may be sub-
ject to internal reference pricing (Table 1). This means a common reimbursement level is set
for a group of medicinal products. Internal reference pricing could also contribute to the
demand-side, if the biosimilars are presented with lower prices than their reference medicinal
products. This is the case in Bulgaria, where physicians are recommended to prescribe biosimi-
lars for treatment-naïve patients.
Demand-side policies. Approximately half of the countries have incentives targeting phy-
sicians to prescribe biosimilars, as can be seen in Table 1. Within the context of a convention
providing specific supplementary remuneration based on attaining public health objectives
(re´mune´ration sur objectifs de sante´ publique, ROSP), a new measure was introduced in
France in 2016, which encourages physicians to prescribe at least 20% insulin glargine bio-
similars in ambulatory care [29]. Belgium’s ‘Pact of the future’ for the patient with the pharma-
ceutical industry [30], which aims to ensure patient access to innovate treatments, fosters
innovation, and creates a new deontological framework for the pharmaceutical industry, pro-
vided the basis for a covenant between the government, the pharmaceutical industry and the
medical sector to stimulate the use of biosimilars [30, 31]. In this context, physicians are
encouraged to prescribe at least 20% biosimilars for treatment-naïve patients. In Germany,
quotas exist for some biosimilars within the context of regionally negotiated economic targets.
Table 1. (Continued)
Country Biosimilar pricing in ambulatory care Internal reference
pricing
Incentives to
prescribe
Substitution
Sweden HTA, a cost effectiveness analysis, is the base for decisions on pricing of a
biosimilar. The price of the biosimilar needs to be the same or lower than the price
of the reference product.
No Yes, regional No
ASMR: Ame´lioration du Service Me´dical Rendu, CEPS: Comite´ e´conomique des produits de sante´ (Economic Committee for Medicinal Products), EU:
European Union, EFTA: European Free Trade Association, EEA: European Economic Area, HTA: Health technology assessment, INN: International
nonproprietary name, JAZMP: Javna agencija Republike Slovenije za zdravila in medicinske pripomočke (Slovenian Agency for medicinal products and
medical devices), NHS: National Health Service
https://doi.org/10.1371/journal.pone.0190147.t001
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In addition, there can be incentives for physicians to prescribe economically, e.g., in Austria
the physician is called upon to prescribe the most cost-effective product when several therapy
options are available, providing an incentive for physicians to prescribe biosimilars. Also in
Belgium, biosimilars are part of quotas for prescribing low-cost medicines [32]. Most countries
mention budgetary restrictions playing a role in prescribing a biosimilar. In the Netherlands,
limitation of prescription of the originator medicinal product once the biosimilar has entered
the market is sometimes enforced by insurance companies for reimbursement purposes.
In some countries, physician incentives have been incorporated in pricing and reimburse-
ment mechanisms with a view to stimulate biosimilar uptake. For instance, in Norway, all
products paid by the hospitals (also some for outpatient use) are subject to tendering. A rank-
ing is then made by the Norwegian Hospital Procurement Trust, Division Pharmaceuticals
(LIS) based on price, and a recommendation is written. The physicians have to follow the
ranking and use the cheapest product, which often is a biosimilar, except when there is a clini-
cal reason not to use the cheapest product. With this system, biosimilar infliximab has reached
a market share above 95%, and also the market share of biosimilar etanercept has been increas-
ing to above 82%.
Substitution may also influence the uptake of biosimilars. Substitution is defined by the
EMA and the European Commission as: “The practice of dispensing one medicine instead of
another equivalent and interchangeable medicine at pharmacy level without consulting the pre-
scriber.” [33] In most countries substitution of biological medicines is not allowed, except for
Estonia, France, Latvia, Poland, and Russia (Table 1). In Estonia, medicinal products for
ambulatory use have to be prescribed by INN. As a result, substitution concerns treatment-
naïve patients as well as patients previously treated with a biological. The pharmacist will
inform the patient about the cheapest alternative. Patients can refuse biosimilar substitution,
but then have to pay the price difference between the originator medicinal product and the
biosimilar out-of-pocket. The physician can prevent substitution through medical justification.
In France, legislation allowing substitution of biosimilars has been introduced as part of a new
law concerning the social security budget (Art 96 of the 2017 French Social Security Financing
Law) and is limited to specific conditions. Substitution is allowed only for treatment-naïve
patients initiating treatment (specified by the physician on the prescription) or to ensure conti-
nuity with the same biosimilar, if the biosimilar belongs to the same group as the prescribed
product (similar biologic group), and if the prescribing physician has not explicitly prohibited
substitution. If the pharmacist substitutes the prescribed biological for the biosimilar, they
must write down the name of the dispensed product on the prescription and inform the pre-
scribing physician. To date, no implementing decree has been enacted, thus in practice substi-
tution is not yet taking place. Latvia also allows for substitution at the pharmacy level. If a
doctor has prescribed the originator medicinal product and has not indicated on the prescrip-
tion that the prescribed medicine may not be substituted, it is the duty of the pharmacist to
inform the patient about the cheapest alternative. Patients can refuse biosimilar substitution,
but then have to pay the price difference between the originator medicinal product and the
biosimilar. For newly diagnosed patients, INN prescribing has to be used, and then the duty of
the pharmacist is to dispense the cheapest reimbursable medicinal product, conforming to the
name, pharmaceutical form and strength. The patient cannot choose. In Poland, substitution
is allowed by law within reference groups, and the pharmacist should discuss substitution with
the patient. In Russia, physicians prescribe by INN, but they can prevent substitution by pro-
viding a medical reason. Patients can refuse and explain their reasons to the physician, or they
can buy the brand name out-of-pocket. In Germany, subgroups of bioidenticals are defined
for some biologicals [34], where pharmacist substitution is allowed unless specifically for-
bidden by the prescribing physician, the so-called Aut-idem-Regelung (i.e., rules regarding
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same-substance substitution). Bioidenticals are biosimilars to the same reference product and
produced by the same manufacturer and manufacturing process, but marketed under different
trade names, e.g., Inflectra1 and Remsima1.
A variety of educational policies are implemented across countries. In most countries, local
initiatives exist among physicians in hospitals or ambulatory care. Also prescribing guidelines
and clinical guidelines can inform physicians. In some countries, including Portugal and the
Netherlands, scientific conferences are organized by, e.g., health authorities, to educate stake-
holders and stimulate the use of biosimilars. In Norway, the Norwegian Hospital Procurement
Trust, Division Pharmaceuticals (LIS) arranges every year several seminars for hospitals,
where results of the tenders are presented. In addition, lectures are organized of which several
discussed the topic of biosimilars. Reported educational policies tend to target in the first
instance physicians, whereas fewer policies were reported for patients. Patients are mainly
informed via patient organizations (e.g., via educational initiatives and surveys) or leaflets
(e.g., a patient brochure in Portugal, explaining what a biosimilar is), or via letters when
exposed to a switch.
iii) Recommendations as proposed by the country experts
It was clear for each country that various hurdles exist to the development of the biosimilar
market and that the full potential of biosimilars is not yet captured. Possible solutions were
suggested to overcome these obstacles, and although some were country-specific, we list here
overall recommendations derived from the survey results to support market uptake of
biosimilars.
The main hurdle for all countries was limited knowledge of biosimilars among key stake-
holders and the lack of education, especially for physicians and patients. It is important that
physicians and patients can make an informed decision. There is a clear need for more infor-
mation and better communication on the use of biosimilars. This information should come
from an independent institution and should be precise and reliable. Lessons and trainings
could be organized, for example in hospitals, where most biosimilars will be prescribed or at
least the therapy is initiated. For patients, a questions and answers (Q&A) document could
help to address frequently asked questions. The use of a common platform to share experi-
ences and knowledge was suggested, and also ongoing publication of safety and efficacy data,
so that evidence-based decisions can be made. Furthermore, concerns related to switching and
substitution possibilities, and the definition of a treatment-naïve patient should be addressed.
Introduction of biosimilars in prescribing guidelines and clinical guidelines will be key to
ensure increased uptake.
Competitive, sustainable pricing is needed. Some suggested the price difference should be
large enough to incentivize physicians or to use obligatory price reductions for the originator
medicinal product. National tendering, tendering by INN, and a ‘product of the month’-sys-
tem could be effective to achieve lower prices. HTA could assist in budget planning, and help
incentivize physicians. Pharmaceutical companies and national authorities should collaborate,
on a national level as well as between countries, to support affordability through competitive
price systems.
Several experts noted that, if switching from the originator medicinal product to the biosi-
milar is accepted as a principle, then there should be more support for this process. The bur-
den of switching now lies with the prescribing physician, and monitoring of patients on a
biosimilar can be very resource intensive. Switching programs can for example be supported
via insurance companies, but also pharmaceutical companies could provide supportive infra-
structure (e.g., IT infrastructure), which supports pooling of data between different centers.
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Gain sharing, which is here defined as an incentive where part of the savings from using biosi-
milars goes to the hospital or prescribing physician, is also suggested as a meaningful solution.
A hurdle that was identified by the country experts is that the EMA, which has all the data
on the reference medicinal product, does not decide on biosimilar substitution and derogates
this decision to the Member States. The question of interchangeability needs to be addressed at
the European level as well. The development of a list for appropriate substitution would help.
One of the experts offered mandatory use of the cheapest product, as decided by health author-
ities, as a measure to assist biosimilar uptake.
Furthermore, experts agreed that measures should be introduced to promote rational pre-
scribing, and that adherence to these measures should be verified. For treatment-naïve patients
it is generally accepted that they can safely be started on the biosimilar. Here, quota can help to
increase uptake of biosimilars.
The experts find leadership is needed on policies, and for this transparency and trust between
the different stakeholders is key. It was proposed by some country experts that payer and insur-
ance companies could be in the right position to lead on prescribing changes. However, biosimi-
lar policies have to include all stakeholders, from patient groups, doctors, hospitals to national
institutions responsible for pricing and reimbursement. A multi-stakeholder approach is
deemed needed in the exercise leading to a more effective allocation of available resources in
view of optimal global health management. A clear strategy and a stratified prioritization exer-
cise for the allocation of resources is needed. HTA can assist in reimbursement decisions.
Discussion
This article has presented a comprehensive overview of different policies for biosimilars in
Europe, and has elicited recommendations from experts to enhance their uptake. Our article
has mapped the diversity of biosimilar policies implemented in European countries, and
showed that policy makers have adopted different approaches in supporting the biosimilar
market.
Our study adds to the scarce literature about biosimilar uptake policies. Although Renwick
et al. performed a literature review in 2016 on post-market policy considerations for biosimilar
oncology drugs [15], our study included all biosimilars available at that point and used a ques-
tionnaire and close collaboration with the experts for recent information and insight in their
country. A recent quantitative study by Re´muzat et al. corroborated the importance of map-
ping biosimilar uptake policies as they found that biosimilar market penetration is higher
when supported by uptake policies [13]. Identification of national policies in this study was
done via a literature review [14].
i) Availability of biosimilars
Our study inquired about the setting in which a product is available. However, S1 Table only
shows whether it is possible to receive a specific active substance in ambulatory care or in the
hospital setting. Via which setting a product is mainly distributed cannot be determined. Com-
plex, expensive products are often distributed via the hospital, e.g., infliximab.
This study shows which biosimilars are funded for the selected countries. However, funding
of a biosimilar is no indication of the actual use of the biosimilar in a country. Recently
approved biosimilars, as Inflectra1 and Remsima1, seem to be well accepted and integrated
in the healthcare systems of the different countries. On the one hand, this may suggest there is
a high need for lower cost alternatives for these complex and expensive molecules, in contrast
to simpler molecules, like insulin, epoetin, and follitropin. On the other hand, this might indi-
cate an increasing trust in the biosimilar pathway. This evolution will become clear in the
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upcoming years, knowing the pipeline of biosimilars (both monoclonal antibodies as well as
smaller biologicals) [35].
ii) National policies
Our analysis indicated that originator and biosimilar products may be subjected to internal ref-
erence pricing systems in two thirds of countries. If these products are included in the same ref-
erence group, this implicitly means that the originator product and the biosimilar product are
considered to be interchangeable. This is noteworthy because the EMA does not assess inter-
changeability when considering the marketing authorization of a biosimilar. It can thus be
inferred that the in/exclusion of originator and biosimilar products in internal reference pricing
is likely to reflect the different positions of European countries towards interchangeability
within the context of switching. Starting treatment-naïve patients on a biosimilar is generally
accepted as safe, but no consensus exists among countries for switching of existing patients [8].
Approximately half of the countries have implemented specific incentives targeting physi-
cians, such as quota. Quota arrangements require physicians to prescribe a minimum percent-
age of biosimilars when prescribing a biological medicine. When quotas are in place, it is
important that adherence to this quota can be verified, for example, by prescription monitor-
ing. Quotas which are not binding tend to miss their target, as is the case in several regions in
Italy, where the individual regions autonomously regulate market access and thus can intro-
duce measures on biosimilar use.
Although most European countries do not allow biosimilar substitution at the pharmacy
level, our results showed that several countries are implementing pharmacist substitution,
even though the scope and rules governing such substitution tend to vary between these coun-
tries. In the study of Reiland et al. (an update of the 2014 EBE survey) it is noted that over the
last years additional countries are allowing pharmacy-level substitution of biologicals [36]. To
date, there is a lack of knowledge about pharmacist biosimilar substitution practices in general,
and the impact of various conditions governing substitution in particular. These will be
research areas for the future.
Although healthcare professionals and patients appreciate that the pharmaceutical budget is
finite and that biosimilars can help to sustain healthcare, their knowledge and experience with
biosimilars tends to be limited [37–39]. In response to this, the European Commission has
issued Q&A documents about biosimilars targeting healthcare professionals and patients [33,
40, 41], and also individual countries have started initiatives to educate stakeholders and help
combat misconceptions and misinformation [42]. Limited literature exists in which clear edu-
cational approaches are proposed. Possible ways of increasing awareness are integrating biosi-
milars in the curriculum of pharmacy students [43], and dissemination of positions statements
by scientific or professional societies, for example the European Society for Medical Oncology
(ESMO) [44]. Our experts additionally highlighted the need for unbiased information, pre-
scribing guidelines, and training schools for practicing healthcare professionals.
iii) Recommendations as proposed by the country experts
It was proposed by the country experts to use mandatory price reductions on the originator
biological. Although this may lead to savings in the healthcare budget, it may turn into a disin-
centive for companies developing a biosimilar, by eroding their competitive advantage and
limiting their return on investment [14].
As indicated before, the European Commission plays an important role in education of
stakeholders and the distribution of information from independent institutions [33, 40, 41], as
recommended by the different country experts. An increasing number of publications on the
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safety and efficacy of biosimilars can be found [45–47], for example results of the Norwegian
government funded NOR-SWITCH trial on the safety of switching from originator infliximab
to its biosimilar version, CT-P13 [48].
However, a disincentive exists for healthcare providers that switch to the biosimilar, requir-
ing extra time and efforts. This can be solved by a mechanism called gain sharing, i.e. that
healthcare providers are rewarded in some way for their efforts to introduce cost savings into
the healthcare system.
Limitations
Our study suffered from several limitations. Our analysis was based on a general questionnaire
that allowed us to carry out a comparative analysis of biosimilar policies between countries,
but was less adapted to the local policy environment and may not have picked up country-spe-
cific information. As a result, there might have been difficulties with interpreting and answer-
ing the questions. Additionally, experts might not know about the various initiatives that exist
in their country, and local policies. In response to this limitation, open boxes were added to
elaborate on each question and after each theme experts were asked if they had additional
comments on the questions in that theme. This permitted experts to provide additional coun-
try-specific information. Finally, experts reviewed the manuscript to decrease interpretation
errors and to add additional information.
Using initially one expert per country could raise questions on the validity of the answers.
This was mitigated by supplementing the data with relevant literature, and contact with extra
experts. Since the questionnaire was only available in English, this could have potentially
excluded suitable experts, although contacted experts have functions which imply that an
intermediary to advanced level of English is present.
Future research
Our study that mapped biosimilar uptake policies can provide a platform for further research
that quantifies the impact of specific policies on the biosimilar uptake level, or that contrasts
high-uptake countries with low-uptake countries and the relation of biosimilar uptake with
the implementation of specific policies.
Conclusion
This article has mapped biosimilar uptake policies in 24 countries and identified possible
approaches that were proposed by local experts to enhance the uptake of biosimilars in Europe.
This mapping exercise underlines that countries are implementing a variety of biosimilar
uptake policies, highlighting the need for future studies to learn from this experience and to
investigate the impact of specific policies on biosimilar uptake levels.
Most countries have put in place specific supply-side policies for promoting access to biosimi-
lars. To supplement these measures, we propose that investments should be made by individual
countries, and on a European level, to clearly communicate on biosimilars and educate stakehold-
ers. Especially physicians who prescribe treatments with biological medicinal products need to
be informed on the entry and use of biosimilars in order to create trust in these products. When
physicians are well-informed on the treatment options, further incentives should be offered to
prescribe biosimilars. Gain sharing can be used as an incentive to prescribe, dispense or use biosi-
milars. This approach, in combination with binding quota, may support a sustainable biosimilar
market. It seems the attitude of countries towards substitution of biologicals is changing, with sev-
eral countries implementing (restricted) pharmacist substitution. This may indicate growing
importance of incentives targeting pharmacists to dispense biosimilars.
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